• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy.

作者信息

Olson Erin M

机构信息

Richard J. Solove Research Institute, Columbus, OH 43210, USA.

出版信息

J Clin Oncol. 2012 May 10;30(14):1712-4. doi: 10.1200/JCO.2011.40.2545. Epub 2012 Mar 5.

DOI:10.1200/JCO.2011.40.2545
PMID:22393085
Abstract
摘要

相似文献

1
Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy.最大化人表皮生长因子受体2抑制作用：靶向治疗时代的一种新肿瘤学模式。
J Clin Oncol. 2012 May 10;30(14):1712-4. doi: 10.1200/JCO.2011.40.2545. Epub 2012 Mar 5.
2
Doubling down on human epidermal growth factor receptor 2.加倍关注人类表皮生长因子受体2
J Clin Oncol. 2012 May 10;30(14):1574-6. doi: 10.1200/JCO.2011.40.1463. Epub 2012 Mar 5.
3
HER2 testing in patients with breast cancer.乳腺癌患者的人表皮生长因子受体2检测
BMJ. 2012 Jun 11;344:e3958. doi: 10.1136/bmj.e3958.
4
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?选择最佳的基于曲妥珠单抗的辅助化疗方案：我们应该摒弃蒽环类药物吗？
J Clin Oncol. 2012 Jun 20;30(18):2179-82. doi: 10.1200/JCO.2012.42.0695. Epub 2012 May 21.
5
PIK3CA genotype and treatment decisions in human epidermal growth factor receptor 2-positive breast cancer.人表皮生长因子受体2阳性乳腺癌中的PIK3CA基因型与治疗决策
J Clin Oncol. 2015 Apr 20;33(12):1318-21. doi: 10.1200/JCO.2014.59.3160. Epub 2015 Jan 5.
6
[The requirements to clinicopathology about targeted therapy for breast cancer].[乳腺癌靶向治疗的临床病理学要求]
Zhonghua Bing Li Xue Za Zhi. 2007 Jul;36(7):435-7.
7
How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers.我们应该降到多低？探索人表皮生长因子受体2阳性小乳腺癌管理中的平衡
J Clin Oncol. 2014 Jul 10;32(20):2122-4. doi: 10.1200/JCO.2014.55.7249. Epub 2014 Jun 2.
8
Dual HER2 blockade slows metastatic breast cancer.双重HER2阻断可延缓转移性乳腺癌的进展。
Cancer Discov. 2012 Jan;2(1):OF4. doi: 10.1158/2159-8290.CD-ND121511OL-12. Epub 2011 Dec 15.
9
Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.血清表皮生长因子与曲妥珠单抗联合紫杉烷类化疗一线治疗 HER2 阳性转移性乳腺癌患者的预后和激素受体状态相关。
Cancer Chemother Pharmacol. 2013 Nov;72(5):1023-9. doi: 10.1007/s00280-013-2268-9. Epub 2013 Sep 15.
10
Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.分析HER家族（HER1-4）表达作为帕妥珠单抗、曲妥珠单抗和多西他赛联合治疗晚期HER2阳性乳腺癌的生物标志物
Anticancer Res. 2018 Apr;38(4):2285-2294. doi: 10.21873/anticanres.12473.

引用本文的文献

1
HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment.HER2 扩增型肝内胆管癌具有高突变负担和 T 细胞耗竭微环境。
J Cancer Res Clin Oncol. 2024 Aug 28;150(8):403. doi: 10.1007/s00432-024-05894-0.
2
Prognostic Significance of EGFR, HER2, and c-Met Overexpression in Surgically Treated Patients with Adenocarcinoma of the Ampulla of Vater.表皮生长因子受体（EGFR）、人表皮生长因子受体2（HER2）和c-甲硫氨酸（c-Met）过表达在接受手术治疗的壶腹腺癌患者中的预后意义
Cancers (Basel). 2024 Aug 3;16(15):2756. doi: 10.3390/cancers16152756.
3
Impact of the Protein Data Bank on antineoplastic approvals.
蛋白数据库对抗肿瘤药物批准的影响。
Drug Discov Today. 2020 May;25(5):837-850. doi: 10.1016/j.drudis.2020.02.002. Epub 2020 Feb 14.
4
How Structural Biologists and the Protein Data Bank Contributed to Recent FDA New Drug Approvals.结构生物学家和蛋白质数据库如何助力近期 FDA 新药审批。
Structure. 2019 Feb 5;27(2):211-217. doi: 10.1016/j.str.2018.11.007. Epub 2018 Dec 27.
5
PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.PD-L1 表达和 CD8 阳性 T 细胞与 HER2 阳性浸润性乳腺癌的良好生存相关。
Breast J. 2018 Nov;24(6):911-919. doi: 10.1111/tbj.13112. Epub 2018 Sep 19.
6
Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.采用多重免疫组化法评估 HER2 阳性乳腺癌的免疫反应和 PD-L1 表达：与抗 HER2 新辅助治疗反应的相关性。
Clin Breast Cancer. 2018 Apr;18(2):e237-e244. doi: 10.1016/j.clbc.2017.11.001. Epub 2017 Nov 9.
7
The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis.在Her2阳性乳腺癌患者中，曲妥珠单抗和拉帕替尼添加至新辅助化疗的有效性和安全性：一项随机荟萃分析。
Onco Targets Ther. 2016 May 30;9:3233-47. doi: 10.2147/OTT.S106055. eCollection 2016.
8
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.拉帕替尼联合曲妥珠单抗的新辅助双HER2靶向治疗可改善早期HER2阳性乳腺癌患者的病理完全缓解率：一项随机前瞻性临床试验的荟萃分析
Oncologist. 2015 Apr;20(4):337-43. doi: 10.1634/theoncologist.2014-0334. Epub 2015 Mar 2.
9
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer.曲妥珠单抗-美坦新偶联物在治疗人表皮生长因子受体 2 阳性乳腺癌中的作用。
Breast Cancer (Dove Med Press). 2014 Jul 23;6:103-13. doi: 10.2147/BCTT.S67297. eCollection 2014.
10
Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.曲妥珠单抗辅助治疗后 HER2 阳性乳腺癌患者首发中枢神经系统转移的发生率和风险。
Ann Oncol. 2013 Jun;24(6):1526-33. doi: 10.1093/annonc/mdt036. Epub 2013 Mar 4.